Articles related to GLAUCOMA

Statin use was associated with lower open-angle glaucoma incidence and fewer glaucoma procedures in a large retrospective matched cohort, although the observational design did not establish a protective or causal effect.

A retrospective review of glaucoma referrals found that optometrists submitted more complete clinical documentation than ophthalmologists, although key diagnostic information was frequently absent from referrals originating from either provider group.

A 10-year retrospective cohort study associated glaucoma with higher risks of Alzheimer disease, vascular dementia, and other neurodegenerative diagnoses, although administrative coding and surveillance bias limit causal interpretation.

The FDA classified a recall of dorzolamide and timolol ophthalmic solution as a Class II event after reports of defective containers, affecting a specific lot used to treat glaucoma and ocular hypertension.

Systemic nicotinamide exposure was associated with a lower risk of conversion from ocular hypertension to primary open-angle glaucoma in a large real-world cohort. Patients receiving nicotinamide also had lower rates of topical therapy initiation and laser trabeculoplasty, although the study did not establish causality.

CMS proposed 2027 Physician Fee Schedule changes that would reduce reimbursement for certain same-day evaluation and management services performed with procedures. Ophthalmology organizations warned the changes could affect glaucoma treatment workflows, although the proposal remains under review.